EPL Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Broad-based 9.2% revenue growth, margin recovery intact: EBITDA margin rose 282 bps YoY to 17.9%, the fourth straight quarter of improvement, driven by softening costs, mix and productivity.
• Brazil plant now commercial, ramp-up underway: The state-of-the-art facility is fully operational and integrated with SAP; July saw a step-up in volume, though the company is not yet near target ramp-up numbers.
• Pricing cycle has turned: Price hikes are now few and far between, and pass-through of input cost reductions has begun flowing as negative pricing for contracted customers, tempering optical revenue.
• Demand softness in the West, realism in the tone: Management is realistic about the US and "a little more pessimistic" about Europe, while India remains solid and China is lapping a low base.
• What to watch next quarter: Whether Brazil volumes reach a stable, guidable run-rate; the pace of Americas margin recovery as one-off health insurance costs reverse; and any further demand deterioration in Europe.

Topline & Volume Drivers

• Revenue growth was 9.2%, broad-based across all regions: AMESA grew 5% despite Egyptian pound devaluation; EAP bounced back with 11.5% double-digit growth; Europe grew 7.8%; Americas grew 9.5%.
• Personal care now 49% of total sales: The category's rising share reflects a deliberate mix shift, with management renewing efforts to push harder behind Beauty & Cosmetics where global share is low and headroom is large.
• India standalone growth of ~6.9% is a mix story, not share loss: The company has actually built market share; the number reflects a combination of margin, mix and pricing that will normalize as the year progresses.
• China is lapping a low base with some structural tailwind: A shift away from China for exports by large multinationals is already in the base, while exports out of China to places like Thailand remain robust. Management is watchful of how the overall environment plays out.
• Sequential comparisons mislead because of seasonality: The business has product-mix shifts across Beauty, Pharma and Oral that affect margins sequentially; management insists YoY is the proper assessment lens.

Kripalu: "From a revenue standpoint this is business with some seasonality. So, sequential comparisons, we don't really believe reflect the performance of the company. It is Y-o-Y. You have to look at the same quarter the previous year to get a proper assessment of how we are performing."

Margins: Recovery, One-Offs & the Pricing Cycle

• EBITDA margin recovered 282 bps YoY to 17.9%: Absolute EBITDA grew 29.6%, the fourth straight quarter of margin increase, driven by softening input costs, active price management, mix improvement and productivity.
• Americas margins were subdued by a timing-related health insurance one-off: The cost hit this quarter will nullify over the course of the year; there is a clear plan for margin recovery that includes growing the business and structural cost changes.
• The pricing cycle has turned decisively: Price hikes are now few and far between; whatever had to come have come. For contracted customers, pass-through of input cost reductions has started flowing through as negative pricing, tempering optical revenue numbers without implying the company is not pushing growth harder.
• Europe carries a significant margin opportunity as growth returns: Management sees room to improve margins in the region when the demand environment strengthens.
• Management will not give a margin-ambition number: The commitment is to continuous improvement and to a level that keeps the company competitive, with the explicit caveat that margins cannot be increased indefinitely.

Kripalu: "I think one has to recognize that there will be a tempering of pricing, not so much in terms of positive pricing, but there will be some negative pricing as well, that were flowing through and some of it has started flowing through particularly for contracted customers already."

Brazil: Ramp-Up, Pipeline & the Wait for Steady-State

• The plant is fully operational and integrated with SAP: Commercial production and delivery are underway; the facility is state-of-the-art.
• Q1 was soft on volume as trials dominated: July saw a step-up in ramp-up with sizable volume, but the company is nowhere near the ramp-up numbers it wants. Apart from a month here or there, the trajectory is broadly on track.
• A new customer order is very close: Management disclosed on the call that they are very close to having got an order from one new customer in Brazil.
• The customer pipeline is building on multinational interest: Teams are in active conversation with several customers and connected with many global MNCs present on the ground in Brazil; momentum in widening the customer base is building.
• Steady-state guidance is at least a quarter away: Management declined to share revenue run-rate, utilization level or profitability, saying it is too early to give any steady-state indication.

Demand Environment & Regional Realism

• India remains solid, the West is softening: Demand softness is visible in the US and particularly in Europe, where management is "a little more pessimistic given the overall environment."
• China benefits from export shifts but bears watching: Some shift away from China for exports by large multinationals is already in the base, and exports out of China to places like Thailand remain robust. Management is being watchful of how China plays out.
• Egypt created a short-term translation headwind: The devaluation of the Egyptian pound impacted AMESA's reported growth, which was 5% including that drag.

Kripalu: "I think we remain more, what should I say, realistic about what's going to happen in the US, but probably a little more pessimistic given the overall environment in Europe."

Capital Allocation & Tax

• Effective tax rate guided at ~26%-27% for FY24: The rate will also depend on certain dividends from subsidiaries; management asked for one more quarter for full visibility but said previous Q4 guidance can be maintained.
• The balance sheet can take more leverage for growth: Debt is tracked on ratios (DSCR, ICR, debt equity); if growth opportunities arise, the company has headroom to increase leverage.
• Management declined to share EBITDA per ton by product: Geography-level data is available in the investor deck, but product-level granularity is not disclosed.
• Pricing and volume granularity were also withheld: Management does not normally share the kind of granular data that would let investors split absolute EBITDA growth into volume versus pricing drivers.

Guidance & Commitments

Key Metrics